Novartis

Latest articles

4h
Philly.com
Cascade of costs could push Penn-pioneered gene therapy above $1 million per patientcancer care has focused on skyrocketing drug prices, including the $475,000 pri
Philly.com / Posted 4 hours ago
cancer care has focused on skyrocketing drug prices, including the $475,000 price tag for the country’s first gene therapy, Novartis’ Kymriah, a leukemia treatment approved in August. But the total costs of Kymriah and the 21 similar drugs in... Read more
5h
Detroit Free Press
New gene therapy treatment could hit $1M per patient because of additional costsimagined, reaching $1 million or more per patient, according to leading cancer
Detroit Free Press / Posted 5 hours ago
imagined, reaching $1 million or more per patient, according to leading cancer experts. The therapy, a leukemia drug from Novartis called Kymriah, was approved in August with an eye-popping sticker price of $475,000 for a one-time treatment. But... Read more
19h
Broomfield Enterprise
Novartis division closing Broomfield operationsNovartis, a global health care company based in Switzerland, is closing its San
Broomfield Enterprise / Posted 19 hours ago
Novartis, a global health care company based in Switzerland, is closing its Sandoz division in Broomfield at 2555 W. Midway Blvd. The site is a manufacturing facility for generic drugs. Approximately 450 jobs will be affected as a result of the... Read more
2 related articles
23h
Broomfield Enterprise
Novartis division closing Broomfield operationsNovartis, a global health care company based in Switzerland, is closing its Bro
Broomfield Enterprise / Posted 23 hours ago
Novartis, a global health care company based in Switzerland, is closing its Broomfield manufacturing plant at 2555 W. Midway Blvd. Approximately 450 jobs will be affected as a result of the closure, Novartis spokeswoman Sofina Mirza-Reid said this... Read more
2 related articles
23h
Boulder Daily Camera
Novartis division closing Broomfield operationsNovartis, a global health care company based in Switzerland, is closing its Bro
Boulder Daily Camera / Posted 23 hours ago
Novartis, a global health care company based in Switzerland, is closing its Broomfield manufacturing plant at 2555 W. Midway Blvd. Approximately 450 jobs will be affected as a result of the closure, Novartis spokeswoman Sofina Mirza-Reid said this... Read more
2 related articles
1d
The Scientist
Will the Noninvasive Glucose Monitoring Revolution Ever Arrive?approach is to work with external fluids. For example, researchers from a high-
The Scientist / Posted yesterday
approach is to work with external fluids. For example, researchers from a high-profile collaboration between Google and Novartis announced in 2014 that they are developing a “smart contact lens” to measure glucose concentrations in diabetes... Read more
1d
Zero Hedge
Hedge Fund CIO: "Never In Human History Have So Many Things That Weigh Nothing Had So Much Value"Volkswagen $13.6, Intel $12.7bln, Samsung $12.5bln, Microsoft $12.3bln, Roche $
Zero Hedge / Posted yesterday
Volkswagen $13.6, Intel $12.7bln, Samsung $12.5bln, Microsoft $12.3bln, Roche $11.4bln, Merck $10.1bln, Apple $10bln, Novartis $9.0bln, Johnson & Johnson $9bln, Huawei $8.4bln, General Motors $8.1bln, Toyota $8.0, Pfizer $7.8bln, Ford $7.1bln,... Read more
1d
Boston Globe
The potential of gene therapy is breathtaking. So is the price tag.response. That way, if the treatment stops working for a given patient, he or s
Boston Globe / Posted yesterday
response. That way, if the treatment stops working for a given patient, he or she might not have to pay the full amount. Novartis is taking a baby step in this direction with its newly approved CAR-T cancer drug, Kymriah. It’s priced at $475,000,... Read more
3 related articles
4d
The Daily Californian
Private research: Industry-funded research takes on a larger role on a cash-strapped campusAt UC Berkeley, Pfizer sponsors research into drug development strategy. Intel
The Daily Californian / Posted 4 days ago
At UC Berkeley, Pfizer sponsors research into drug development strategy. Intel supports secure computing research. Novartis backs research targeting “undruggable diseases.” More and more, the funders of UC Berkeley research are of a corporate, and... Read more
4d
FOX Business
A New FDA Approval Sends Small Cap Flexion Soaringhere that has a 20 mg biosimilar of Copaxone. This is a company called Momenta
FOX Business / Posted 4 days ago
here that has a 20 mg biosimilar of Copaxone. This is a company called Momenta (NASDAQ: MNTA), which is partnered with Novartis on the biosimilar. So that's another thing to consider. It's not hugely important, because Momenta only reported... Read more
4d
FOX Business
A New FDA Approval Sends Small Cap Flexion Soaringhere that has a 20 mg biosimilar of Copaxone. This is a company called Momenta
FOX Business / Posted 4 days ago
here that has a 20 mg biosimilar of Copaxone. This is a company called Momenta (NASDAQ: MNTA), which is partnered with Novartis on the biosimilar. So that's another thing to consider. It's not hugely important, because Momenta only reported... Read more
4d
FOX 16 Little Rock
Drug Manufacturers Now Offering Purchase Protectionfrom going up. "It's increasing accountability and transparency for drugs and
FOX 16 Little Rock / Posted 4 days ago
from going up. "It's increasing accountability and transparency for drugs and drug effectiveness," said Dr. Fendrick. Novartis, which makes some drugs that offer rebates and guarantees, says that "by collaborating with payers on outcome based... Read more
4d
The Washington Times
NIH launches $215 million research partnership for cancer immunotherapiesSquibb, Celgene, Genetech, Gilead Sciences, Janssen Pharmaceutical Companies of
The Washington Times / Posted 4 days ago
Squibb, Celgene, Genetech, Gilead Sciences, Janssen Pharmaceutical Companies of Johnson and Johnson, Pfizer and Novartis – agree to a “pre-competitive” research collaboration that will establish a data base that all the companies will... Read more
5d
Business Wire
Model N Announces Date of Fourth Quarter and Fiscal Year 2017 Financial Resultstechnology and manufacturing across more than 100 countries, including Johnson
Business Wire / Posted 5 days ago
technology and manufacturing across more than 100 countries, including Johnson & Johnson, AstraZeneca, Boston Scientific, Novartis, Microchip Technology and ON Semiconductor. For more information, visit www.modeln.com. Model N® is the registered... Read more
5d
WECT 6 Wilmington
Money back guarantees for prescription drugsfrom going up. “It’s increasing accountability and transparency for drugs and
WECT 6 Wilmington / Posted 5 days ago
from going up. “It’s increasing accountability and transparency for drugs and drug effectiveness,” Dr. Fendrick said. Novartis, which makes some drugs that offer rebates and guarantees, says “by collaborating with payers on outcome-based... Read more
6d
Reuters
Novartis decides not to sell Roche stake chairman tells newspaperZURICH (Reuters) - Novartis (NOVN.S) has decided not to sell its roughly $14 bi
Reuters / Posted 6 days ago
ZURICH (Reuters) - Novartis (NOVN.S) has decided not to sell its roughly $14 billion (10.61 billion pounds), 33 percent voting stake in Roche (ROG.S) following a review, Chairman Joerg Reinhardt said in an interview published on Wednesday in Swiss... Read more
6d
New Kerala
JoAnne Stubbe of MIT Will Receive the 2017 Pearl Meister Greengard Prize - newkerala news #279557Meister Greengard Prize, the preeminent international award honoring outstandin
New Kerala / Posted 6 days ago
Meister Greengard Prize, the preeminent international award honoring outstanding women scientists. Dr. Stubbe, who is the Novartis Professor of Chemistry and Biology Emeritus at the Massachusetts Institute of Technology, will receive the 14th... Read more
6d
FOX Business
Amgen Wins Reprieve on Its 2nd-Best-Selling Drugto convince regulators in the U.S. and Europe that they've created knockoffs th
FOX Business / Posted 6 days ago
to convince regulators in the U.S. and Europe that they've created knockoffs that warrant a green light. Last year, Novartis(NYSE: NVS) received an FDA rejection for its Neulasta biosimilar, which prompted it to withdraw its application for... Read more
6d
FOX Business
Amgen Wins Reprieve on Its 2nd-Best-Selling Drugto convince regulators in the U.S. and Europe that they've created knockoffs th
FOX Business / Posted 6 days ago
to convince regulators in the U.S. and Europe that they've created knockoffs that warrant a green light. Last year, Novartis(NYSE: NVS) received an FDA rejection for its Neulasta biosimilar, which prompted it to withdraw its application for... Read more
6d
New Kerala
WomenHeart Commences the 16th Annual Science and Leadership Symposium at Mayo Clinic in Rochester - newkerala news #279401women living with or at risk of heart disease. The fall 2017 WomenHeart Scienc
New Kerala / Posted 6 days ago
women living with or at risk of heart disease. The fall 2017 WomenHeart Science & Leadership Symposium is sponsored by Novartis, Mylan, Amgen, Boston Scientific, Abbott Vascular, with donated facility from the Mayo Clinic in Rochester,... Read more
7d
Business Wire
Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancerthe DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
Business Wire / Posted 7 days ago
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc. Forward Looking Statement for Seattle... Read more
8d
Business Wire
Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicinepractice at McKinsey and Company and subsequently appointed director and head o
Business Wire / Posted 8 days ago
practice at McKinsey and Company and subsequently appointed director and head of the New Indications Discovery Unit at Novartis. Dr. Saha is on the editorial boards of numerous prestigious medical journals and is an associate member and global... Read more
10d
FOX Business
3 Blockbuster Drugs That Still Cost More Than They Shouldthan they should.2. Enbrel: Lawyer-palooza California's Amgen might have the i
FOX Business / Posted 10 days ago
than they should.2. Enbrel: Lawyer-palooza California's Amgen might have the industry's most fearsome legal team. Novartis is learning this the hard way as it tries to launch biosimilar versions of Amgen's best-selling... Read more
10d
FOX Business
3 Blockbuster Drugs That Still Cost More Than They Shouldthan they should.2. Enbrel: Lawyer-palooza California's Amgen might have the i
FOX Business / Posted 10 days ago
than they should.2. Enbrel: Lawyer-palooza California's Amgen might have the industry's most fearsome legal team. Novartis is learning this the hard way as it tries to launch biosimilar versions of Amgen's best-selling... Read more
11d
Arkansas Democrat-Gazette
Maria damage tests drugmakersto work its way through the system, and there's a gap behind it," said William
Arkansas Democrat-Gazette / Posted 11 days ago
to work its way through the system, and there's a gap behind it," said William McLaury, who worked in supply chain for Novartis AG for three decades and is now an assistant professor of professional practice at Rutgers Business School. "If... Read more
11d
Business Wire
ImmunoGen Announces Pricing of Public Offering of Common Stockin Roche’s marketed product, Kadcyla® and in programs in development by Amgen,
Business Wire / Posted 11 days ago
in Roche’s marketed product, Kadcyla® and in programs in development by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis, Sanofi and Takeda. Kadcyla® is a registered trademark of Genentech, a member of the Roche Group. This press... Read more
11d
FOX Business
Why Glaukos Corp. Stock Sank 12.8% in Septembera row. Predictably, that kind of success hasn't gone unnoticed by the big playe
FOX Business / Posted 11 days ago
a row. Predictably, that kind of success hasn't gone unnoticed by the big players in eye care. Last year, healthcare giant Novartis acquired Transcend Medical to get its hands on the company's CyPass Micro-Stent. Since the CyPass was approved last... Read more
11d
FOX Business
Why Glaukos Corp. Stock Sank 12.8% in Septembera row. Predictably, that kind of success hasn't gone unnoticed by the big playe
FOX Business / Posted 11 days ago
a row. Predictably, that kind of success hasn't gone unnoticed by the big players in eye care. Last year, healthcare giant Novartis acquired Transcend Medical to get its hands on the company's CyPass Micro-Stent. Since the CyPass was approved last... Read more
12d
The Economic Times
Novartis divests anti-infectives brands to Samara Capital Fosun Pharma acquires 74% stake in Gland Pharma for $1.09 billion After Gl
The Economic Times / Posted 12 days ago
Fosun Pharma acquires 74% stake in Gland Pharma for $1.09 billion After Gland, Chinese pharma giant Fosun eyes API maker... Read more
12d
Swissinfo
Swiss blue-chip CEOs dominate European wage ranking€5.63 million and Germany €5.06 million. The Swiss companies included ABB, Cred
Swissinfo / Posted 12 days ago
€5.63 million and Germany €5.06 million. The Swiss companies included ABB, Credit Suisse Group, LafargeHolcim, Nestlé, Novartis, Roche Holding and UBS. Richemont, Swiss Re, Syngenta and Zurich Insurance Group were not included in the evaluation... Read more
12d
Business Wire
Global Smoking Cessation Aids Market, 2022 - Key Players are GSK, Pfizer, Novartis, Johnson and Johnson & Ciplaof drug as a smoking cessation aid. The key players in smoking cessation thera
Business Wire / Posted 12 days ago
of drug as a smoking cessation aid. The key players in smoking cessation therapy market are GlaxoSmithKline, Pfizer, Novartis, Johnson and Johnson, Cipla Ltd. And others. Key Topics Covered: 1. Introduction 2. Executive Summary 3. Market... Read more
12d
Gulf News
Aon Hewitt names 'best employers' in UAE, rest of Middle Easthonoured at an awarding ceremony in Dubai this week, included DHL (Bahrain, Ira
Gulf News / Posted 12 days ago
honoured at an awarding ceremony in Dubai this week, included DHL (Bahrain, Iraq, Jordan, Lebanon, Oman, Qatar and UAE), Novartis Pharma (Levant), Rotana Hotel Management Corporation (Lebanon and Iraq), Marriott International and Marriott... Read more
12d
citybizlist Dallas
TechFW Client Ayuvis Honored for Defense Innovationmore than 15 years of cumulative academic and pharmaceutical experience with UT
citybizlist Dallas / Posted 12 days ago
more than 15 years of cumulative academic and pharmaceutical experience with UT Southwestern Medical Center, Alcon Labs and Novartis. AyuVis Research was founded in 2014 and has received funding from the National Institutes of Health. Acharya also... Read more
13d
FOX Business
A Generic Drug Face-Off Sends Mylan Soaring 19%about $4 billion in annual sales for Teva Pharmaceutical, and Momenta Pharmaceu
FOX Business / Posted 13 days ago
about $4 billion in annual sales for Teva Pharmaceutical, and Momenta Pharmaceuticals markets a 20 mg biosimilar with Novartis that's likely to get prescribed less frequently now that Mylan's 20 mg and 40 mg versions are available. Last... Read more
11 related articles
13d
FOX Business
A Generic Drug Face-Off Sends Mylan Soaring 19%about $4 billion in annual sales for Teva Pharmaceutical, and Momenta Pharmaceu
FOX Business / Posted 13 days ago
about $4 billion in annual sales for Teva Pharmaceutical, and Momenta Pharmaceuticals markets a 20 mg biosimilar with Novartis that's likely to get prescribed less frequently now that Mylan's 20 mg and 40 mg versions are available. Last... Read more
11 related articles
13d
Business Standard India
US is pressing India to avoid capping medical device prices, allow withdrawalsNovartis is addressing the pricing question with a new type of agreement: For p
Business Standard India / Posted 13 days ago
Novartis is addressing the pricing question with a new type of agreement: For patients whose care is covered by the US govt programmes, the company will only get paid if patients show signs that the treatment is working within a month | Photo:... Read more
3 related articles
14d
Newsmax
World's First Universal Flu Vaccine to be Testedinto final Phase III tests," he said. Leading manufacturers of seasonal flu va
Newsmax / Posted 14 days ago
into final Phase III tests," he said. Leading manufacturers of seasonal flu vaccines include Sanofi, GlaxoSmithKline and CSL's Seqirus, which includes the old Novartis flu vaccine business. (Reporting by Ben Hirschler, editing by Louise H... Read more
53 related articles
14d
Eye Witness News
Oxford team to test universal flu vaccine in world firstwould look for a better-capitalised company to take this into final Phase III t
Eye Witness News / Posted 14 days ago
would look for a better-capitalised company to take this into final Phase III tests,” he said. Leading manufacturers of seasonal flu vaccines include Sanofi, GlaxoSmithKline and CSL’s Seqirus, which includes the old Novartis flu vaccine bu... Read more
53 related articles
14d
Sky News Australia
UK team to test universal flu vaccineis the first time a universal flu vaccine has progressed beyond Phase I clinica
Sky News Australia / Posted 14 days ago
is the first time a universal flu vaccine has progressed beyond Phase I clinical testing. Leading manufacturers of seasonal flu vaccines include Sanofi, GlaxoSmithKline and CSL's Seqirus, which includes the old Novartis flu vaccine business. Reut... Read more
53 related articles
14d
Herald Sun
UK team to test universal flu vaccineis the first time a universal flu vaccine has progressed beyond Phase I clinica
Herald Sun / Posted 14 days ago
is the first time a universal flu vaccine has progressed beyond Phase I clinical testing. Leading manufacturers of seasonal flu vaccines include Sanofi, GlaxoSmithKline and CSL's Seqirus, which includes the old Novartis flu vacci... Read more
53 related articles
14d
Australian Broadcasting Corporation
Oxford researchers team to test universal flu vaccinewould look for a better-capitalised company to take this into final Phase III t
Australian Broadcasting Corporation / Posted 14 days ago
would look for a better-capitalised company to take this into final Phase III tests," he said. Leading manufacturers of seasonal flu vaccines include Sanofi, GlaxoSmithKline and CSL's Seqirus, which includes the old Novartis flu vaccine bu... Read more
53 related articles
14d
Adelaide Now
UK team to test universal flu vaccineis the first time a universal flu vaccine has progressed beyond Phase I clinica
Adelaide Now / Posted 14 days ago
is the first time a universal flu vaccine has progressed beyond Phase I clinical testing. Leading manufacturers of seasonal flu vaccines include Sanofi, GlaxoSmithKline and CSL's Seqirus, which includes the old Novartis flu vacci... Read more
53 related articles
14d
The Courier Mail
UK team to test universal flu vaccineis the first time a universal flu vaccine has progressed beyond Phase I clinica
The Courier Mail / Posted 14 days ago
is the first time a universal flu vaccine has progressed beyond Phase I clinical testing. Leading manufacturers of seasonal flu vaccines include Sanofi, GlaxoSmithKline and CSL's Seqirus, which includes the old Novartis flu vacci... Read more
53 related articles
14d
News.com.au
UK team to test universal flu vaccineis the first time a universal flu vaccine has progressed beyond Phase I clinica
News.com.au / Posted 14 days ago
is the first time a universal flu vaccine has progressed beyond Phase I clinical testing. Leading manufacturers of seasonal flu vaccines include Sanofi, GlaxoSmithKline and CSL's Seqirus, which includes the old Novartis flu vacci... Read more
53 related articles
14d
Business Wire
Celyad annonce une première réponse complète chez un patient atteint de LMA réfractaire et récidivante dans l’essai THINKles attentes de Celyad concernant ses collaborations stratégiques et ses accord
Business Wire / Posted 14 days ago
les attentes de Celyad concernant ses collaborations stratégiques et ses accords de licence avec des tiers, dont Novartis, Celdara Medical et Dartmouth College, et l'impact potentiel de ces collaborations sur la situation financière... Read more
284 related articles
14d
Business Wire
Celyad Reports a First Complete Response in a Relapsed Refractory AML Patient in the THINK Trialthereto; Celyad’s expectations regarding its strategic collaborations and licen
Business Wire / Posted 14 days ago
thereto; Celyad’s expectations regarding its strategic collaborations and license agreements with third parties, including Novartis, Celdara Medical, and Dartmouth College, and the potential impact of such collaborations on Celyad’s future... Read more
14d
The Young Witness
Don't create policy, tax uncertainty: CSL chief's plea to Turnbullcapital management program. Entry into China CSL still has not made a return o
The Young Witness / Posted 14 days ago
capital management program. Entry into China CSL still has not made a return on the $US275 million acquisition of the Novartis influenza business, which is now called Seqirus. But Mr Perreault said it had secured multiple new product... Read more
15d
The Gilmer Mirror
Do Pharma’s Claims On Drug Prices Pass The Smell Test? We Found 5 Stinkers. - Do Pharma’s Claims On Drug Prices Pass The Smell Test? We Found 5 Stinkers. Jay Hancock Kaiser Health News Drug companies launched an ad and publicity extravaganza this ...arriving to market, often involving living cells and gene therapy, look more ex
The Gilmer Mirror / Posted 15 days ago
arriving to market, often involving living cells and gene therapy, look more expensive than ever. The announced cost for Novartis’ Kymriah therapy for kids with leukemia is $475,000 for a one-time treatment. Drug companies seem to show concern... Read more
15d
Business Wire
KSQ Therapeutics Emerges with $76 Million in Financing to Pioneer High-Confidence Drug DevelopmentBoard Member. Dr. Stegmeier is a leading expert in industrialized functional ge
Business Wire / Posted 15 days ago
Board Member. Dr. Stegmeier is a leading expert in industrialized functional genomics who led Oncology Target Discovery at Novartis prior to joining KSQ. He has led KSQ’s platform development and R&D efforts since the company’s formation in 2015,... Read more
15d
The Daily Californian
UC Berkeley researchers partners with Novartis to develop new curesResearchers from UC Berkeley and major pharmaceutical company Novartis are coll
The Daily Californian / Posted 15 days ago
Researchers from UC Berkeley and major pharmaceutical company Novartis are collaborating to develop new drugs for diseases currently unable to be targeted by drugs. The virtual center will use chemoproteomic technologies to develop new treatments... Read more
More

In this news